In this book the authors review the field and explore the potential role of RNAi and other RNA technologies in cardiovascular medicine and research. They highlight the impressive recent progress but also the hurdles that still must be overcome before this promising technology is finally ready for translation and clinical use.

Hersteller:
Springer Verlag GmbH
juergen.hartmann@springer.com
Tiergartenstr. 17
DE 69121 Heidelberg

InhaltsangabePreface.- Part I - MicroRNA.- An overview of microRNA. MicroRNAs and their potential. miRNAs and their emerging role in cardiac hypertrophy. MicroRNAs and the control of heart pathophysiology. MicroRNA systems biology.- Part II - RNA interference.- Targeting viral heart disease by RNA interference. Design of siRNAs and shRNAs for RNA interference: possible clinical applications. RNA interference and microRNA modulation for the treatment of cardiac disorders. Cardiac delivery of nucleic acids by transcriptional and transductional targeting of adeno-associated viral vectors.- Part III - Ribozymes.- Characterization of hammerhead ribozymes potentialy suitable for the treatment of hyperproliferative vascular diseases. Applications of ribozymes and pyrrole-imidazole polyamides for cardiovascular and renal diseases.- Part IV. - Noncoding, aptamer and antisense RNAs.- Noncoding RNAs in human diseases. Aptamers and siRNAs in cardiovascular disease. Nucleic Acid Aptamers for Cardiovascular Therapeutics. NFkB decoy oligodeoxynucleotide-based therapy in cardiovascular diseases. Antisense therapy for restenosis following percutaneous coronary intervention.Toxic RNA in pathogenesis of human neuromuscular disorders.